Stephen L. Bandak
Directeur/Membre du Conseil chez Hapten Sciences, Inc.
Profil
Stephen L.
Bandak is currently the Director at Hapten Sciences, Inc. and a Member of The Royal College of Physicians since 1977.
He was previously the Vice President-Medical & Regulatory Affairs at Novavax, Inc. and the Chief Medical Officer at Synosia Therapeutics AG from 2007 to 2011, at Biotie Therapies Oy from 2011 to 2016, and at Synosia Therapeutics, Inc. from 2007 to 2011.
Postes actifs de Stephen L. Bandak
| Sociétés | Poste | Début |
|---|---|---|
Hapten Sciences, Inc.
 Hapten Sciences, Inc. Pharmaceuticals: MajorHealth Technology Hapten Sciences, Inc. is a biopharmaceutical company. It identifies and develops novel, early-stage products that contribute to the health and well being of people around the world. Its product include PDC-APB, a small molecule that acts like a vaccine to prevent the extremely painful itching and rash. The company was founded by Raymond Joseph Hage Jr. and is headquartered in Memphis, TN. | Directeur/Membre du Conseil | - |
| The Royal College of Physicians | Corporate Officer/Principal | 01/01/1977 |
Anciens postes connus de Stephen L. Bandak
| Sociétés | Poste | Fin |
|---|---|---|
| BIOTIE THERAPIES CORP | Directeur Technique/Scientifique/R&D | 30/06/2016 |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Synosia Therapeutics, Inc.
 Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
| NOVAVAX, INC. | Directeur Technique/Scientifique/R&D | 19/09/2011 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVAVAX, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Synosia Therapeutics, Inc.
Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Hapten Sciences, Inc.
Hapten Sciences, Inc. Pharmaceuticals: MajorHealth Technology Hapten Sciences, Inc. is a biopharmaceutical company. It identifies and develops novel, early-stage products that contribute to the health and well being of people around the world. Its product include PDC-APB, a small molecule that acts like a vaccine to prevent the extremely painful itching and rash. The company was founded by Raymond Joseph Hage Jr. and is headquartered in Memphis, TN. | Health Technology |
